1998
DOI: 10.1006/rtph.1997.1163
|View full text |Cite
|
Sign up to set email alerts
|

Do Peroxisome Proliferating Compounds Pose a Hepatocarcinogenic Hazard to Humans?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
127
1
5

Year Published

2001
2001
2023
2023

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 214 publications
(135 citation statements)
references
References 68 publications
2
127
1
5
Order By: Relevance
“…P450 monooxygenases mediate peroxisomal proliferationperoxisome proliferation-unresponsive species, such as humans (55,56).…”
Section: Discussionmentioning
confidence: 99%
“…P450 monooxygenases mediate peroxisomal proliferationperoxisome proliferation-unresponsive species, such as humans (55,56).…”
Section: Discussionmentioning
confidence: 99%
“…However, nonrodent species were shown to be refractory to the induction of peroxisome proliferation (33). In fact, the fibrate class of PPAR-␣ agonists has been safely used in humans to treat hypertriglyceridemia, and no hepatic carcinogenesis has been reported (34). Although the effect of PPAR-␣ activation on insulin sensitivity is inconclusive in humans, some recent clinical studies have shown improved insulin sensitivity by fibrates (35,36).…”
Section: Discussionmentioning
confidence: 99%
“…Such peroxisome proliferation is ultimately associated with an increased incident of hepatocarcinoma (Lake, 1995). However, it has been subsequently found that such PPAR agonists do not induce peroxisome proliferation (or cancer) in a number of species including guinea pigs, primates and humans (Cattley et al, 1998;Choudhury et al, 2000). In fact, fibrates, known PPARa ligands, have been commonly used in the treatment of elevated plasma lipids for many years (Watts and Dimmitt, 1999).…”
Section: Nuclear Receptorsmentioning
confidence: 99%